What if I miss a weekly injection
It depends on the treatment sought and the patient's metabolism, which will determine the answer to this question

Insulin Sensitivity and Beta-Cell Function Research demonstrated that GLP2 produces improvements in fundamental metabolic dysfunction: Approximately 8% reduction in HOMA2-IR (insulin resistance marker) with 10 mg dose Enhanced markers of beta-cell function including improved insulin secretory responses Greater insulin sensitivity improvements compared to selective GLP-1 receptor agonists Lower prandial insulin and glucagon concentrations compared to active comparators Obesity and Weight Management SURMOUNT Clinical Trials The SURMOUNT program investigated GLP2 for chronic weight management in participants with obesity or overweight: SURMOUNT-1 (adults without diabetes): Mean weight loss up to 20.9% (approximately 48 pounds) with 15 mg dose at 72 weeks compared to 3.1% with placebo SURMOUNT-2 (adults with type 2 diabetes): Mean weight loss up to 15.7% (34.4 pounds) with 15 mg dose at 72 weeks 55-63% of participants achieved at least 20% body weight reduction with higher doses Greater weight loss than achieved with selective GLP-1 receptor agonists in head-to-head comparisons Weight loss with GLP2 included favorable body composition changes, with fat-mass to lean-mass loss ratios similar to lifestyle interventions and bariatric surgery

The addition of the C-18 fatty acid moiety to Lys26 is hypothesized to increase the binding dose-response ratio due to an increased albumin affinity
Results from Tirzepatide at Magnolia Functional Wellness vary based on individual factors, treatment protocol, and your specific goals
Losing muscle mass and strength can lead to sarcopenia [age-related involuntary muscle loss], which increases the risk for functional decline, disability, nursing home placement, and death. Strength training and a protein-rich diet can help reduce loss of muscle and bone, but shedding pounds quickly may inhibit the bodys ability to adjust, Batsis notes